Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer

Shoichi Hazama, Hiroko Takenouchi, Ryouichi Tsunedomi, Michihisa Iida, Nobuaki Suzuki, Norio Iizuka, Yuka Inoue, Kazuhiko Sakamoto, Mitsuhiro Nakao, Yoshitaro Shindo, Shinsuke Kanekiyo, Yukio Tokumitsu, Kiyoshi Yoshimura, Noriko Maeda, Kazunari Maeda, Yoshinari Maeda, Hiroto Matsui, Shigefumi Yoshino, Yusuke Nakamura, Yusuke FujitaYoshihiko Hamamoto, Masato Okamoto, Tomonobu Fujita, Yutaka Kawakami, Masaaki Oka

研究成果: Article査読

17 被引用数 (Scopus)


Background: We previously reported a phase I study of a cancer vaccine using five novel HLA-A∗2402-restricted peptides, and demonstrated the safety and the promising potential of our five-peptide cocktail for advanced colorectal cancer. The objective of this analysis was to investigate predictive biomarkers for the prior selection of patients who are likely to have clinical benefit from such therapy. Patients and Methods: Seventeen patients with colorectal cancer who were treated with the five peptides underwent a complete blood count, serum chemistry tests and enzyme-linked ImmunoSpot assay before the treatment as predictive markers of high reactivity to the peptides. Results: Interleukin-6 level was a significant predictor for overall survival of patients treated with the peptide cocktail (p=0.017). A high neutrophil/lymphocyte ratio was likely to have some association with the poor induction of peptide-specific immune reaction. Conclusion: Interleukin-6 level might be a good predictive biomarker for clinical benefit of patients treated with this peptide vaccine.

ジャーナルAnticancer research
出版ステータスPublished - 2014 8月 1

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究


「Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。